Cargando…

The C Allele of ATM rs11212617 Associates With Higher Pathological Complete Remission Rate in Breast Cancer Patients Treated With Neoadjuvant Metformin

Background: The minor allele (C) of the single-nucleotide polymorphism (SNP) rs11212617, located near the ataxia telangiectasia mutated (ATM) gene, has been associated with an increased likelihood of treatment success with metformin in type 2 diabetes. We herein investigated whether the same SNP wou...

Descripción completa

Detalles Bibliográficos
Autores principales: Cuyàs, Elisabet, Buxó, Maria, Ferri Iglesias, Maria José, Verdura, Sara, Pernas, Sonia, Dorca, Joan, Álvarez, Isabel, Martínez, Susana, Pérez-Garcia, Jose Manuel, Batista-López, Norberto, Rodríguez-Sánchez, César A., Amillano, Kepa, Domínguez, Severina, Luque, Maria, Morilla, Idoia, Stradella, Agostina, Viñas, Gemma, Cortés, Javier, Joven, Jorge, Brunet, Joan, López-Bonet, Eugeni, Garcia, Margarita, Saidani, Samiha, Queralt Moles, Xavier, Martin-Castillo, Begoña, Menendez, Javier A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6447648/
https://www.ncbi.nlm.nih.gov/pubmed/30984619
http://dx.doi.org/10.3389/fonc.2019.00193
_version_ 1783408539012694016
author Cuyàs, Elisabet
Buxó, Maria
Ferri Iglesias, Maria José
Verdura, Sara
Pernas, Sonia
Dorca, Joan
Álvarez, Isabel
Martínez, Susana
Pérez-Garcia, Jose Manuel
Batista-López, Norberto
Rodríguez-Sánchez, César A.
Amillano, Kepa
Domínguez, Severina
Luque, Maria
Morilla, Idoia
Stradella, Agostina
Viñas, Gemma
Cortés, Javier
Joven, Jorge
Brunet, Joan
López-Bonet, Eugeni
Garcia, Margarita
Saidani, Samiha
Queralt Moles, Xavier
Martin-Castillo, Begoña
Menendez, Javier A.
author_facet Cuyàs, Elisabet
Buxó, Maria
Ferri Iglesias, Maria José
Verdura, Sara
Pernas, Sonia
Dorca, Joan
Álvarez, Isabel
Martínez, Susana
Pérez-Garcia, Jose Manuel
Batista-López, Norberto
Rodríguez-Sánchez, César A.
Amillano, Kepa
Domínguez, Severina
Luque, Maria
Morilla, Idoia
Stradella, Agostina
Viñas, Gemma
Cortés, Javier
Joven, Jorge
Brunet, Joan
López-Bonet, Eugeni
Garcia, Margarita
Saidani, Samiha
Queralt Moles, Xavier
Martin-Castillo, Begoña
Menendez, Javier A.
author_sort Cuyàs, Elisabet
collection PubMed
description Background: The minor allele (C) of the single-nucleotide polymorphism (SNP) rs11212617, located near the ataxia telangiectasia mutated (ATM) gene, has been associated with an increased likelihood of treatment success with metformin in type 2 diabetes. We herein investigated whether the same SNP would predict clinical response to neoadjuvant metformin in women with early breast cancer (BC). Methods: DNA was collected from 79 patients included in the intention-to-treat population of the METTEN study, a phase 2 clinical trial of HER2-positive BC patients randomized to receive either metformin combined with anthracycline/taxane-based chemotherapy and trastuzumab or equivalent regimen without metformin, before surgery. SNP rs11212617 genotyping was assessed using allelic discrimination by quantitative polymerase chain reaction. Results: Logistic regression analyses revealed a significant relationship between the rs11212617 genotype and the ability of treatment arms to achieve a pathological complete response (pCR) in patients (odds ratio [OR](genotype×arm) = 10.33, 95% confidence interval [CI]: 1.29–82.89, p = 0.028). In the metformin-containing arm, patients bearing the rs11212617 C allele had a significantly higher probability of pCR (OR(A/C,C/C) = 7.94, 95%CI: 1.60–39.42, p = 0.011). Conversely, no association was found between rs11212617 and clinical response in the reference arm (OR(A/C,C/C) = 0.77, 95%CI: 0.20–2.92, p = 0.700). After controlling for tumor size and hormone receptor status, the rs11212617 C allele remained a significant predictor of pCR solely in the metformin-containing arm. Conclusions: If reproducible, the rs11212617 C allele might warrant consideration as a predictive clinical biomarker to inform the personalized use of metformin in BC patients. Trial Registration: EU Clinical Trials Register, EudraCT number 2011-000490-30. Registered 28 February 2011, https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-000490-30/ES.
format Online
Article
Text
id pubmed-6447648
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-64476482019-04-12 The C Allele of ATM rs11212617 Associates With Higher Pathological Complete Remission Rate in Breast Cancer Patients Treated With Neoadjuvant Metformin Cuyàs, Elisabet Buxó, Maria Ferri Iglesias, Maria José Verdura, Sara Pernas, Sonia Dorca, Joan Álvarez, Isabel Martínez, Susana Pérez-Garcia, Jose Manuel Batista-López, Norberto Rodríguez-Sánchez, César A. Amillano, Kepa Domínguez, Severina Luque, Maria Morilla, Idoia Stradella, Agostina Viñas, Gemma Cortés, Javier Joven, Jorge Brunet, Joan López-Bonet, Eugeni Garcia, Margarita Saidani, Samiha Queralt Moles, Xavier Martin-Castillo, Begoña Menendez, Javier A. Front Oncol Oncology Background: The minor allele (C) of the single-nucleotide polymorphism (SNP) rs11212617, located near the ataxia telangiectasia mutated (ATM) gene, has been associated with an increased likelihood of treatment success with metformin in type 2 diabetes. We herein investigated whether the same SNP would predict clinical response to neoadjuvant metformin in women with early breast cancer (BC). Methods: DNA was collected from 79 patients included in the intention-to-treat population of the METTEN study, a phase 2 clinical trial of HER2-positive BC patients randomized to receive either metformin combined with anthracycline/taxane-based chemotherapy and trastuzumab or equivalent regimen without metformin, before surgery. SNP rs11212617 genotyping was assessed using allelic discrimination by quantitative polymerase chain reaction. Results: Logistic regression analyses revealed a significant relationship between the rs11212617 genotype and the ability of treatment arms to achieve a pathological complete response (pCR) in patients (odds ratio [OR](genotype×arm) = 10.33, 95% confidence interval [CI]: 1.29–82.89, p = 0.028). In the metformin-containing arm, patients bearing the rs11212617 C allele had a significantly higher probability of pCR (OR(A/C,C/C) = 7.94, 95%CI: 1.60–39.42, p = 0.011). Conversely, no association was found between rs11212617 and clinical response in the reference arm (OR(A/C,C/C) = 0.77, 95%CI: 0.20–2.92, p = 0.700). After controlling for tumor size and hormone receptor status, the rs11212617 C allele remained a significant predictor of pCR solely in the metformin-containing arm. Conclusions: If reproducible, the rs11212617 C allele might warrant consideration as a predictive clinical biomarker to inform the personalized use of metformin in BC patients. Trial Registration: EU Clinical Trials Register, EudraCT number 2011-000490-30. Registered 28 February 2011, https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-000490-30/ES. Frontiers Media S.A. 2019-03-28 /pmc/articles/PMC6447648/ /pubmed/30984619 http://dx.doi.org/10.3389/fonc.2019.00193 Text en Copyright © 2019 Cuyàs, Buxó, Ferri Iglesias, Verdura, Pernas, Dorca, Álvarez, Martínez, Pérez-Garcia, Batista-López, Rodríguez-Sánchez, Amillano, Domínguez, Luque, Morilla, Stradella, Viñas, Cortés, Joven, Brunet, López-Bonet, Garcia, Saidani, Queralt Moles, Martin-Castillo and Menendez. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Cuyàs, Elisabet
Buxó, Maria
Ferri Iglesias, Maria José
Verdura, Sara
Pernas, Sonia
Dorca, Joan
Álvarez, Isabel
Martínez, Susana
Pérez-Garcia, Jose Manuel
Batista-López, Norberto
Rodríguez-Sánchez, César A.
Amillano, Kepa
Domínguez, Severina
Luque, Maria
Morilla, Idoia
Stradella, Agostina
Viñas, Gemma
Cortés, Javier
Joven, Jorge
Brunet, Joan
López-Bonet, Eugeni
Garcia, Margarita
Saidani, Samiha
Queralt Moles, Xavier
Martin-Castillo, Begoña
Menendez, Javier A.
The C Allele of ATM rs11212617 Associates With Higher Pathological Complete Remission Rate in Breast Cancer Patients Treated With Neoadjuvant Metformin
title The C Allele of ATM rs11212617 Associates With Higher Pathological Complete Remission Rate in Breast Cancer Patients Treated With Neoadjuvant Metformin
title_full The C Allele of ATM rs11212617 Associates With Higher Pathological Complete Remission Rate in Breast Cancer Patients Treated With Neoadjuvant Metformin
title_fullStr The C Allele of ATM rs11212617 Associates With Higher Pathological Complete Remission Rate in Breast Cancer Patients Treated With Neoadjuvant Metformin
title_full_unstemmed The C Allele of ATM rs11212617 Associates With Higher Pathological Complete Remission Rate in Breast Cancer Patients Treated With Neoadjuvant Metformin
title_short The C Allele of ATM rs11212617 Associates With Higher Pathological Complete Remission Rate in Breast Cancer Patients Treated With Neoadjuvant Metformin
title_sort c allele of atm rs11212617 associates with higher pathological complete remission rate in breast cancer patients treated with neoadjuvant metformin
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6447648/
https://www.ncbi.nlm.nih.gov/pubmed/30984619
http://dx.doi.org/10.3389/fonc.2019.00193
work_keys_str_mv AT cuyaselisabet thecalleleofatmrs11212617associateswithhigherpathologicalcompleteremissionrateinbreastcancerpatientstreatedwithneoadjuvantmetformin
AT buxomaria thecalleleofatmrs11212617associateswithhigherpathologicalcompleteremissionrateinbreastcancerpatientstreatedwithneoadjuvantmetformin
AT ferriiglesiasmariajose thecalleleofatmrs11212617associateswithhigherpathologicalcompleteremissionrateinbreastcancerpatientstreatedwithneoadjuvantmetformin
AT verdurasara thecalleleofatmrs11212617associateswithhigherpathologicalcompleteremissionrateinbreastcancerpatientstreatedwithneoadjuvantmetformin
AT pernassonia thecalleleofatmrs11212617associateswithhigherpathologicalcompleteremissionrateinbreastcancerpatientstreatedwithneoadjuvantmetformin
AT dorcajoan thecalleleofatmrs11212617associateswithhigherpathologicalcompleteremissionrateinbreastcancerpatientstreatedwithneoadjuvantmetformin
AT alvarezisabel thecalleleofatmrs11212617associateswithhigherpathologicalcompleteremissionrateinbreastcancerpatientstreatedwithneoadjuvantmetformin
AT martinezsusana thecalleleofatmrs11212617associateswithhigherpathologicalcompleteremissionrateinbreastcancerpatientstreatedwithneoadjuvantmetformin
AT perezgarciajosemanuel thecalleleofatmrs11212617associateswithhigherpathologicalcompleteremissionrateinbreastcancerpatientstreatedwithneoadjuvantmetformin
AT batistalopeznorberto thecalleleofatmrs11212617associateswithhigherpathologicalcompleteremissionrateinbreastcancerpatientstreatedwithneoadjuvantmetformin
AT rodriguezsanchezcesara thecalleleofatmrs11212617associateswithhigherpathologicalcompleteremissionrateinbreastcancerpatientstreatedwithneoadjuvantmetformin
AT amillanokepa thecalleleofatmrs11212617associateswithhigherpathologicalcompleteremissionrateinbreastcancerpatientstreatedwithneoadjuvantmetformin
AT dominguezseverina thecalleleofatmrs11212617associateswithhigherpathologicalcompleteremissionrateinbreastcancerpatientstreatedwithneoadjuvantmetformin
AT luquemaria thecalleleofatmrs11212617associateswithhigherpathologicalcompleteremissionrateinbreastcancerpatientstreatedwithneoadjuvantmetformin
AT morillaidoia thecalleleofatmrs11212617associateswithhigherpathologicalcompleteremissionrateinbreastcancerpatientstreatedwithneoadjuvantmetformin
AT stradellaagostina thecalleleofatmrs11212617associateswithhigherpathologicalcompleteremissionrateinbreastcancerpatientstreatedwithneoadjuvantmetformin
AT vinasgemma thecalleleofatmrs11212617associateswithhigherpathologicalcompleteremissionrateinbreastcancerpatientstreatedwithneoadjuvantmetformin
AT cortesjavier thecalleleofatmrs11212617associateswithhigherpathologicalcompleteremissionrateinbreastcancerpatientstreatedwithneoadjuvantmetformin
AT jovenjorge thecalleleofatmrs11212617associateswithhigherpathologicalcompleteremissionrateinbreastcancerpatientstreatedwithneoadjuvantmetformin
AT brunetjoan thecalleleofatmrs11212617associateswithhigherpathologicalcompleteremissionrateinbreastcancerpatientstreatedwithneoadjuvantmetformin
AT lopezboneteugeni thecalleleofatmrs11212617associateswithhigherpathologicalcompleteremissionrateinbreastcancerpatientstreatedwithneoadjuvantmetformin
AT garciamargarita thecalleleofatmrs11212617associateswithhigherpathologicalcompleteremissionrateinbreastcancerpatientstreatedwithneoadjuvantmetformin
AT saidanisamiha thecalleleofatmrs11212617associateswithhigherpathologicalcompleteremissionrateinbreastcancerpatientstreatedwithneoadjuvantmetformin
AT queraltmolesxavier thecalleleofatmrs11212617associateswithhigherpathologicalcompleteremissionrateinbreastcancerpatientstreatedwithneoadjuvantmetformin
AT martincastillobegona thecalleleofatmrs11212617associateswithhigherpathologicalcompleteremissionrateinbreastcancerpatientstreatedwithneoadjuvantmetformin
AT menendezjaviera thecalleleofatmrs11212617associateswithhigherpathologicalcompleteremissionrateinbreastcancerpatientstreatedwithneoadjuvantmetformin
AT cuyaselisabet calleleofatmrs11212617associateswithhigherpathologicalcompleteremissionrateinbreastcancerpatientstreatedwithneoadjuvantmetformin
AT buxomaria calleleofatmrs11212617associateswithhigherpathologicalcompleteremissionrateinbreastcancerpatientstreatedwithneoadjuvantmetformin
AT ferriiglesiasmariajose calleleofatmrs11212617associateswithhigherpathologicalcompleteremissionrateinbreastcancerpatientstreatedwithneoadjuvantmetformin
AT verdurasara calleleofatmrs11212617associateswithhigherpathologicalcompleteremissionrateinbreastcancerpatientstreatedwithneoadjuvantmetformin
AT pernassonia calleleofatmrs11212617associateswithhigherpathologicalcompleteremissionrateinbreastcancerpatientstreatedwithneoadjuvantmetformin
AT dorcajoan calleleofatmrs11212617associateswithhigherpathologicalcompleteremissionrateinbreastcancerpatientstreatedwithneoadjuvantmetformin
AT alvarezisabel calleleofatmrs11212617associateswithhigherpathologicalcompleteremissionrateinbreastcancerpatientstreatedwithneoadjuvantmetformin
AT martinezsusana calleleofatmrs11212617associateswithhigherpathologicalcompleteremissionrateinbreastcancerpatientstreatedwithneoadjuvantmetformin
AT perezgarciajosemanuel calleleofatmrs11212617associateswithhigherpathologicalcompleteremissionrateinbreastcancerpatientstreatedwithneoadjuvantmetformin
AT batistalopeznorberto calleleofatmrs11212617associateswithhigherpathologicalcompleteremissionrateinbreastcancerpatientstreatedwithneoadjuvantmetformin
AT rodriguezsanchezcesara calleleofatmrs11212617associateswithhigherpathologicalcompleteremissionrateinbreastcancerpatientstreatedwithneoadjuvantmetformin
AT amillanokepa calleleofatmrs11212617associateswithhigherpathologicalcompleteremissionrateinbreastcancerpatientstreatedwithneoadjuvantmetformin
AT dominguezseverina calleleofatmrs11212617associateswithhigherpathologicalcompleteremissionrateinbreastcancerpatientstreatedwithneoadjuvantmetformin
AT luquemaria calleleofatmrs11212617associateswithhigherpathologicalcompleteremissionrateinbreastcancerpatientstreatedwithneoadjuvantmetformin
AT morillaidoia calleleofatmrs11212617associateswithhigherpathologicalcompleteremissionrateinbreastcancerpatientstreatedwithneoadjuvantmetformin
AT stradellaagostina calleleofatmrs11212617associateswithhigherpathologicalcompleteremissionrateinbreastcancerpatientstreatedwithneoadjuvantmetformin
AT vinasgemma calleleofatmrs11212617associateswithhigherpathologicalcompleteremissionrateinbreastcancerpatientstreatedwithneoadjuvantmetformin
AT cortesjavier calleleofatmrs11212617associateswithhigherpathologicalcompleteremissionrateinbreastcancerpatientstreatedwithneoadjuvantmetformin
AT jovenjorge calleleofatmrs11212617associateswithhigherpathologicalcompleteremissionrateinbreastcancerpatientstreatedwithneoadjuvantmetformin
AT brunetjoan calleleofatmrs11212617associateswithhigherpathologicalcompleteremissionrateinbreastcancerpatientstreatedwithneoadjuvantmetformin
AT lopezboneteugeni calleleofatmrs11212617associateswithhigherpathologicalcompleteremissionrateinbreastcancerpatientstreatedwithneoadjuvantmetformin
AT garciamargarita calleleofatmrs11212617associateswithhigherpathologicalcompleteremissionrateinbreastcancerpatientstreatedwithneoadjuvantmetformin
AT saidanisamiha calleleofatmrs11212617associateswithhigherpathologicalcompleteremissionrateinbreastcancerpatientstreatedwithneoadjuvantmetformin
AT queraltmolesxavier calleleofatmrs11212617associateswithhigherpathologicalcompleteremissionrateinbreastcancerpatientstreatedwithneoadjuvantmetformin
AT martincastillobegona calleleofatmrs11212617associateswithhigherpathologicalcompleteremissionrateinbreastcancerpatientstreatedwithneoadjuvantmetformin
AT menendezjaviera calleleofatmrs11212617associateswithhigherpathologicalcompleteremissionrateinbreastcancerpatientstreatedwithneoadjuvantmetformin